Abstract
The rise of antibiotic-resistant pathogens has led to an urgent requirement of potent and safe antimicrobial compounds. Lipopeptides produced as secondary metabolites by some organisms have shown a broad range of anti-pathogenic activities, while some have anti-cancerous properties as well. Among all the lipopeptides, daptomycin has gained popularity as biopharmaceutical. In order for the lipopeptides to be used as drugs, in silico drug designing of these compounds should be performed which enables the identification of the presence of binding sites in lipopeptides for their corresponding ligands. In this study, molecular docking of daptomycin with its ligands was performed as a method of designing novel drug. After the identification of ligands, namely, D-alanine, decanoic acid, D-asparagine, D-serine, (2S)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid, and (2S,3R)-2-azanyl-3-methyl-pentanedioic acid, using RSCB, Schrödinger software was used to dock daptomycin with their corresponding ligands. After the identification of ligands, they were made to dock with daptomycin. The parameters for docking were docking score and glide energy. Out of the six identified ligands of daptomycin, only three were found to dock with it with docking scores of −3.229 (for D-alanine), − (for D-asparagine), and −4.216 (for D-serine). Their respective glide energies were −13.678 kcal/mol (D-alanine), −22.56 kcal/mol (D-asparagine), and −12.042 kcal/mol (D-serine).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Michael CA, Dominey-Howes D, Labbate M (2014) The antimicrobial resistance crisis: causes, consequences, and management. Front Public Health 2. https://doi.org/10.3389/fpubh.2014.00145
Lee SY, Fan HW, Kuti JL, Nicolau DP (2006) Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother 7(10):1381–1397
Ventola CL (2015) The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther 40(4):277
Straus SK, Hancock RE (2006) Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta (BBA)-Biomembr 1758(9):1215–1223
Pálffy R, Gardlίk R, Behuliak M, Kadasi L, Turna J, Celec P (2009) On the physiology and pathophysiology of antimicrobial peptides. Mol Med 15(1–2):51–59
Rotem S, Mor A (2009) Antimicrobial peptide mimics for improved therapeutic properties. Biochim Biophys Acta (BBA)-Biomembr 1788(8):1582–1592
Cotter C, Sturrock HJW, Hsiang MS, Liu J, Philips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RGA (2013) The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 382(9895):900–911
Mandal SM, Barbosa AEAD, Franco OL (2013) Lipopeptides in microbial infection control: scope and reality for industry. Biotechnol Adv 31(2):338–345
Rosenberg E, Ron E (1999) High-and low-molecular-mass microbial surfactants. Appl Microbiol Biotechnol 52(2):154–162
Schneider T, Müller A, Miess H, Gross H (2014) Cyclic lipopeptides as antibacterial agents–potent antibiotic activity mediated by intriguing mode of actions. Int J Med Microbiol 304(1):37–43
Ekins S, Mestres J, Testa B (2007) In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol 152(1):21–37
Jujjavarapu SE, Dhagat S (2018) In silico discovery of novel ligands for antimicrobial lipopeptides for computer-aided drug design. Probiot Antimicrob Proteins 10(2):129–141
Simmons KJ, Chopra I, Fishwick CW (2010) Structure-based discovery of antibacterial drugs. Nat Rev Microbiol 8(7):501–510
Liu H, Gao L, Han J, Ma Z, Lu Z, Dai C, Zhang C, Bie X (2016) Biocombinatorial synthesis of novel lipopeptides by COM domain-mediated reprogramming of the plipastatin NRPS complex. Front Microbiol 7:1801
Verma A, Kumar A, Debnath M (2016) Molecular docking and simulation studies to give insight of surfactin amyloid interaction for destabilizing Alzheimer’s Aβ42 protofibrils. Med Chem Res 25:1616–1622
Eswari JS, Dhagat S, Yadav M (2019) Antifungal lipopeptides. In: Computer-aided design of antimicrobial lipopeptides as prospective drug candidates. CRC Press, Boca Raton, pp 95–102
Jujjavarapu SE, Dhagat S, Kurrey V (2018) Identification of novel ligands for therapeutic lipopeptides: daptomycin, surfactin and polymyxin. Curr Drug Targets 19(13):1589–1598
Steenbergen JN, Alder J, Thorne GM, Francis PT (2005) Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55(3):283–288
Acknowledgments
We are thankful to the National Institute of Technology Raipur and Chhattisgarh Council of Science and Technology (CCOST) (Project number 2487/CCOST/MRP/2016, Raipur dated 25.01.2016), India, for providing the necessary facilities to prepare the manuscript and permission to publish it.
Similarity Index
The similarity index was checked using Turnitin software and was observed to be less than 10%.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Jujjavarapu, S.E., Dhagat, S. (2020). Lipopeptides as Therapeutics: Molecular Docking and Drug Design. In: Sadhukhan, P., Premi, S. (eds) Biotechnological Applications in Human Health. Springer, Singapore. https://doi.org/10.1007/978-981-15-3453-9_7
Download citation
DOI: https://doi.org/10.1007/978-981-15-3453-9_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-3452-2
Online ISBN: 978-981-15-3453-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)